Pain Management
Addressing a Critical
Component of Patient Care
Managing pain in patients’ lives isn’t just an option; it’s a necessity.
- Inadequate pain control is associated with delayed recovery, longer hospital stays, increased healthcare costs, and higher risk of chronic pain development.27
- Effective pain management is central to improving patient outcomes, reducing complications, and enhancing recovery.
- Caldolor offers an option within acute pain management, providing an alternative to opioid treatments. By supporting a more balanced approach to efficacy and tolerability, Caldolor can play a role in optimizing pain control while helping to address the challenges associated with opioid use.28
Evidence Highlighting the Burden of Surgical Pain:
- Chronic postsurgical pain affects approximately 10% of surgical patients, often developing from poorly controlled acute postoperative pain and becoming a persistent, opioid-resistant condition.29
- Severe acute postoperative pain occurs in nearly 20% of patients within the first 24 hours after surgery, a rate that has remained unchanged for over 30 years.30
- In a national US survey of 300 adults who had undergone surgery within the previous 5 years, 86% of patients experienced postsurgical pain overall, and 75% of those who reported pain described its severity as moderate-extreme during the immediate postoperative period.31
- More than 80% of surgical patients experience postoperative pain, and approximately 88% report moderate, severe, or extreme pain levels.32
Consequences and Risks of Poor Pain Control
Impact on Patients27,28,33,34,35
- Chronic pain
- Opioid dependency
- Negative psychological impact
- Impaired physical function
- Decreased quality of life
- Increased morbidity
- Additional medical costs
- Delayed recovery
Impact on Healthcare Systems27,35
- Longer length of stays
- Higher readmission rates
- Increased opioid reliance
- Decreased patient satisfaction
- Increased cost of care
Learn more about how Caldolor can help minimize HCRU.
How Caldolor Supports a Multimodal Pain
Management Approach
- Caldolor offers a proven non-opioid foundation for multimodal pain management. By combining Caldolor with agents acting through different mechanisms, clinicians can achieve superior pain control when minimizing opioid exposure.2,5,6
- Caldolor use prior to and during surgery is consistently associated with reductions in narcotic use across studies.36
- Providers should consider integrating non-opioid analgesics, like Caldolor, to create multimodal, personalized analgesic plans to manage acute pain.34
Explore perioperative analgesia with Caldolor.
Enhancing Recovery and Outcomes
Why does Enhanced Recovery After Surgery (ERAS) matter?
Adopting ERAS Programs Emphasizes37:
- Early mobilization
- Optimized pain control
- Reduction of opioid exposure
- Counteracts adverse physiological consequences of surgical stress and immobilization
- Reduction of postoperative complications
- Accelerated functional walking capacity
- Positive patient outcomes
- Reduced hospital length of stay
- Reduced care costs
Caldolor aligns with these principles by providing rapid, effective, and opioid-sparing analgesia through IV administration.25
Pain Across the Perioperative Continuum
Preoperative initiation and continued postoperative use of Caldolor as part of multimodal analgesia, aligning with American Society of Anesthesiologists (ASA) guidelines for effective pain management, reduced opioid dependence, and improved recovery outcomes.36,38
| Pre-operative | A preemptive 400 mg dose of Caldolor in laparoscopic cholecystectomy reduced postoperative opioid consumption in the 1st 24 hours by 45%. It generated lower pain scores in the postoperative period compared with placebo.39 | Caldolor was more effective than IV acetaminophen for preemptive analgesia in third-molar extraction, with significantly lower post-op pain and opioid use.18 |
| Intra-operative | No increase in post-tonsillectomy bleeding when Caldolor was administered intraoperatively in pediatric tonsillectomy patients.4 | Pre-op and intraoperative 800 mg Caldolor reduced perioperative stress markers (catecholamines, cortisol, and cytokines) and improved the overall quality of recovery, postsurgical fatigue, and early postoperative outcomes.40 |
| Post-operative | Intra-operative and post-op Caldolor 800 mg q6h was associated with a significant morphine sparing effect and with significant reductions in pain at rest and movement compared with placebo.5 | Patients receiving Caldolor pre-op and post-op experienced 30.9% reduction in morphine consumption vs placebo over the postoperative observation period, and a 25.8% reduction in movement-pain AUC and 31.8% reduction in rest-pain AUC.2 |
Caldolor is a nonsteroidal anti-inflammatory drug indicated in adults and pediatric patients aged 3 months and older for the:
- Management of mild to moderate pain, including postoperative pain
- Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics
- Reduction of fever
This Product Includes the Following Boxed Warning:
Warning: Risk of Serious Cardiovascular and Gastrointestinal Events
Cardiovascular Thrombotic Events
- Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
- Caldolor is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Bleeding, Ulceration and Perforation
- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
Important Dosage and Administration Instructions
- Caldolor Injection 800 mg/8 mL (100 mg/mL) vials must be diluted prior to administration.
- Caldolor Injection 800 mg/200 mL (4 mg/mL) bags are ready to use.
- Do not exceed 3,200 mg total daily dose in adults. Do not exceed 40 mg/kg or 2,400 mg, whichever is less, total daily dose in pediatric patients less than 17 years of age. In pediatric patients 3 months to less than 6 months of age, the dosage is limited to a single dose not to exceed 10 mg/kg or 100 mg, whichever is less.
Important Safety Information
Contraindications
- Caldolor is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to ibuprofen or any components of the drug product, and in patients who have a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. Caldolor is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Warnings and Precautions
- Use with caution in patients with known cardiovascular (CV) disease or risk factors for CV disease, a history of peptic ulcer disease and/or GI bleeding, renal or liver disease or symptoms of hypertension, and heart failure. Use the lowest effective dose for the shortest time period in these patients to reduce the risk of serious adverse events. Avoid use in pregnant women starting at 30 weeks gestation.
Adverse Reactions
- The most common adverse reactions are nausea, flatulence, vomiting, headache, hemorrhage and dizziness (>5%). The most common adverse reactions in pediatric patients are infusion site pain, vomiting, nausea, anemia and headache (≥2%)
Have Questions or Would like to Stay Informed About Caldolor?
We’re Here to Help!
